@entity5 immunotherapy using XXXX -fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.

@entity1 @entity43 @entity0 @entity5 @entity792 @entity356 @entity968
Dendritic cell (DC) vaccines might induce both anti- @entity5 immunity and @entity792 . In this report, we demonstrate elevated levels of anti-nuclear antibody (ANA) in the sera of @entity1 with @entity5 who had received immunotherapy with a @entity5 -fusion vaccine. Twenty-two @entity1 were treated with DC vaccine of fusion cells composed of autologous DCs and @entity5 cells (DC/ @entity5 -fusion vaccine), which was generated by treating each cell type with @entity968 . Nine of the 22 @entity1 were treated with both the DC/ @entity5 -fusion vaccine and systemic administration of recombinant @entity1 interleukin (rhIL)-12. Serum levels of ANA were examined with an enzyme-linked immunosorbent assay kit. One @entity1 with @entity356 ( @entity1 1, DC/ @entity5 -fusion vaccine alone), one @entity1 with @entity0 ( @entity1 2, DC/ @entity5 -fusion vaccine alone) and one @entity1 with @entity43 ( @entity1 3, DC/ @entity5 -fusion vaccine + rhIL-12) showed significant elevations of serum ANA levels during treatment. In @entity1 1 @entity5 resolved and serum levels of @entity5 markers decreased. @entity1 2 and 3 remained in good physical condition during treatment for 24 and 9 months, respectively. Immunoblot analysis indicated antibody responses to autologous @entity5 cells after vaccination in @entity1 2. None of the treated @entity1 showed clinical symptoms suggesting @entity792 . @entity1 with elevated serum levels of ANA had significantly longer treatment periods than those without it. Elevated serum levels of ANA after DC/ @entity5 -fusion cell vaccine might be associated with anti- @entity5 immune response induced by the vaccination.
